Login
Evidence Feed
About
Conferences
New
Diagnostics
New
Top genes
New
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
BIOMARKER:
No biomarker
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Associations
News
Twitter
Trials
Reset Filters
VERI cancer hierarchy
x
x
x
x
No biomarker
Prostate Cancer
No biomarker
Prostate Cancer
darolutamide
Sensitive: A1 - Approval
Bayer Press Release - 6 days (New B)
darolutamide
Sensitive
:
A1
Bayer Press Release - 6d
darolutamide
Sensitive: A1 - Approval
Bayer Press Release - 6 days
darolutamide
Sensitive
:
A1
Bayer Press Release - 6 days - (New B)
No biomarker
Mantle Cell Lymphoma
No biomarker
Mantle Cell Lymphoma
pirtobrutinib
Sensitive: A1 - Approval
Eli Lilly Press Release - 6 days (New A1)
pirtobrutinib
Sensitive
:
A1
Eli Lilly Press Release - 6d
pirtobrutinib
Sensitive: A1 - Approval
Eli Lilly Press Release - 6 days
pirtobrutinib
Sensitive
:
A1
Eli Lilly Press Release - 6 days - (New A1)
No biomarker
Non Small Cell Lung Cancer
No biomarker
Non Small Cell Lung Cancer
pembrolizumab
Sensitive: A1 - Approval
FDA - 1 week (New A1)
pembrolizumab
Sensitive
:
A1
FDA - 1wk
pembrolizumab
Sensitive: A1 - Approval
FDA - 1 week
pembrolizumab
Sensitive
:
A1
FDA - 1 week - (New A1)
No biomarker
Multiple Myeloma
No biomarker
Multiple Myeloma
lenalidomide + ixazomib
Sensitive: A1 - Approval
Oncology Central - 1 week (New A2)
lenalidomide + ixazomib
Sensitive
:
A1
Oncology Central - 1wk
lenalidomide + ixazomib
Sensitive: A1 - Approval
Oncology Central - 1 week
lenalidomide + ixazomib
Sensitive
:
A1
Oncology Central - 1 week - (New A2)
No biomarker
Follicular Lymphoma
No biomarker
Follicular Lymphoma
mosunetuzumab
Sensitive: A1 - Approval
NCCN - 1 week (New A2)
mosunetuzumab
Sensitive
:
A1
NCCN - 1wk
mosunetuzumab
Sensitive: A1 - Approval
NCCN - 1 week
mosunetuzumab
Sensitive
:
A1
NCCN - 1 week - (New A2)
No biomarker
Marginal Zone Lymphoma
No biomarker
Marginal Zone Lymphoma
acalabrutinib
Sensitive: A2 - Guideline
NCCN - 1 week (New A2)
acalabrutinib
Sensitive
:
A2
NCCN - 1wk
acalabrutinib
Sensitive: A2 - Guideline
NCCN - 1 week
acalabrutinib
Sensitive
:
A2
NCCN - 1 week - (New A2)
No biomarker
Follicular Lymphoma
No biomarker
Follicular Lymphoma
tazemetostat
Sensitive: A2 - Guideline
NCCN - 1 week (New A2)
tazemetostat
Sensitive
:
A2
NCCN - 1wk
tazemetostat
Sensitive: A2 - Guideline
NCCN - 1 week
tazemetostat
Sensitive
:
A2
NCCN - 1 week - (New A2)
No biomarker
Biliary Tract Cancer
No biomarker
Biliary Tract Cancer
pembrolizumab
Sensitive: B - Late Trials
Merck (MSD) Press Release - 1 week (New B)
pembrolizumab
Sensitive
:
B
Merck (MSD) Press Release - 1wk
pembrolizumab
Sensitive: B - Late Trials
Merck (MSD) Press Release - 1 week
pembrolizumab
Sensitive
:
B
Merck (MSD) Press Release - 1 week - (New B)
No biomarker
Hepatocellular Cancer
No biomarker
Hepatocellular Cancer
bevacizumab + atezolizumab
Sensitive: A1 - Approval
Businesswire - 2 weeks (New B)
bevacizumab + atezolizumab
Sensitive
:
A1
Businesswire - 2wk
bevacizumab + atezolizumab
Sensitive: A1 - Approval
Businesswire - 2 weeks
bevacizumab + atezolizumab
Sensitive
:
A1
Businesswire - 2 weeks - (New B)
No biomarker
Hepatocellular Cancer
No biomarker
Hepatocellular Cancer
sorafenib
Sensitive: A1 - Approval
ASCO-GI 2023 - 2 weeks (New B)
sorafenib
Sensitive
:
A1
ASCO-GI 2023 - 2wk
sorafenib
Sensitive: A1 - Approval
ASCO-GI 2023 - 2 weeks
sorafenib
Sensitive
:
A1
ASCO-GI 2023 - 2 weeks - (New B)
No biomarker
Colorectal Cancer
No biomarker
Colorectal Cancer
fruquintinib
Sensitive: A1 - Approval
ASCO-GI 2023 - 2 weeks (New B)
fruquintinib
Sensitive
:
A1
ASCO-GI 2023 - 2wk
fruquintinib
Sensitive: A1 - Approval
ASCO-GI 2023 - 2 weeks
fruquintinib
Sensitive
:
A1
ASCO-GI 2023 - 2 weeks - (New B)
No biomarker
Small Cell Lung Cancer
No biomarker
Small Cell Lung Cancer
serplulimab
Sensitive: A1 - Approval
Henlius Press Release - 2 weeks (New A1)
serplulimab
Sensitive
:
A1
Henlius Press Release - 2wk
serplulimab
Sensitive: A1 - Approval
Henlius Press Release - 2 weeks
serplulimab
Sensitive
:
A1
Henlius Press Release - 2 weeks - (New A1)
No biomarker
Lung Non-Small Cell Squamous Cancer
No biomarker
Lung Non-Small Cell Squamous Cancer
penpulimab
Sensitive: A1 - Approval
Akeso Biopharma Press Release - 2 weeks (New A1)
penpulimab
Sensitive
:
A1
Akeso Biopharma Press Release - 2wk
penpulimab
Sensitive: A1 - Approval
Akeso Biopharma Press Release - 2 weeks
penpulimab
Sensitive
:
A1
Akeso Biopharma Press Release - 2 weeks - (New A1)
No biomarker
Non Small Cell Lung Cancer
No biomarker
Non Small Cell Lung Cancer
toripalimab
Sensitive: B - Late Trials
BioSpace - 2 weeks (New B)
toripalimab
Sensitive
:
B
BioSpace - 2wk
toripalimab
Sensitive: B - Late Trials
BioSpace - 2 weeks
toripalimab
Sensitive
:
B
BioSpace - 2 weeks - (New B)
No biomarker
Hodgkin Lymphoma
No biomarker
Hodgkin Lymphoma
Bv-AVE-PC
Sensitive: A2 - Guideline
NCCN - 3 weeks (New A2)
Bv-AVE-PC
Sensitive
:
A2
NCCN - 3wk
Bv-AVE-PC
Sensitive: A2 - Guideline
NCCN - 3 weeks
Bv-AVE-PC
Sensitive
:
A2
NCCN - 3 weeks - (New A2)
No biomarker
Hodgkin Lymphoma
No biomarker
Hodgkin Lymphoma
AEPA-CAPDAC
Sensitive: A2 - Guideline
NCCN - 3 weeks (New A2)
AEPA-CAPDAC
Sensitive
:
A2
NCCN - 3wk
AEPA-CAPDAC
Sensitive: A2 - Guideline
NCCN - 3 weeks
AEPA-CAPDAC
Sensitive
:
A2
NCCN - 3 weeks - (New A2)
No biomarker
Hodgkin Lymphoma
No biomarker
Hodgkin Lymphoma
CVbP
Sensitive: A2 - Guideline
NCCN - 3 weeks (New A2)
CVbP
Sensitive
:
A2
NCCN - 3wk
CVbP
Sensitive: A2 - Guideline
NCCN - 3 weeks
CVbP
Sensitive
:
A2
NCCN - 3 weeks - (New A2)
No biomarker
Hodgkin Lymphoma
No biomarker
Hodgkin Lymphoma
CHOP
Sensitive: A2 - Guideline
NCCN - 3 weeks (New A2)
CHOP
Sensitive
:
A2
NCCN - 3wk
CHOP
Sensitive: A2 - Guideline
NCCN - 3 weeks
CHOP
Sensitive
:
A2
NCCN - 3 weeks - (New A2)
No biomarker
Hodgkin Lymphoma
No biomarker
Hodgkin Lymphoma
OEPA
Sensitive: A2 - Guideline
NCCN - 3 weeks (New A2)
OEPA
Sensitive
:
A2
NCCN - 3wk
OEPA
Sensitive: A2 - Guideline
NCCN - 3 weeks
OEPA
Sensitive
:
A2
NCCN - 3 weeks - (New A2)
No biomarker
Hodgkin Lymphoma
No biomarker
Hodgkin Lymphoma
ABVE-PC
Sensitive: A2 - Guideline
NCCN - 3 weeks (New A2)
ABVE-PC
Sensitive
:
A2
NCCN - 3wk
ABVE-PC
Sensitive: A2 - Guideline
NCCN - 3 weeks
ABVE-PC
Sensitive
:
A2
NCCN - 3 weeks - (New A2)
No biomarker
Diffuse Large B Cell Lymphoma
No biomarker
Diffuse Large B Cell Lymphoma
RG6026
Sensitive: B - Late Trials
Roche Press Release - 3 weeks (New B)
RG6026
Sensitive
:
B
Roche Press Release - 3wk
RG6026
Sensitive: B - Late Trials
Roche Press Release - 3 weeks
RG6026
Sensitive
:
B
Roche Press Release - 3 weeks - (New B)
No biomarker
Marginal Zone Lymphoma
No biomarker
Marginal Zone Lymphoma
zanubrutinib
Sensitive: A1 - Approval
zanubrutinib
Sensitive
:
A1
zanubrutinib
Sensitive: A1 - Approval
zanubrutinib
Sensitive
:
A1
No biomarker
Multiple Myeloma
No biomarker
Multiple Myeloma
pomalidomide + elotuzumab
Sensitive: A1 - Approval
pomalidomide + elotuzumab
Sensitive
:
A1
pomalidomide + elotuzumab
Sensitive: A1 - Approval
pomalidomide + elotuzumab
Sensitive
:
A1
No biomarker
Diffuse Large B Cell Lymphoma
No biomarker
Diffuse Large B Cell Lymphoma
lisocabtagene maraleucel
Sensitive: A1 - Approval
lisocabtagene maraleucel
Sensitive
:
A1
lisocabtagene maraleucel
Sensitive: A1 - Approval
lisocabtagene maraleucel
Sensitive
:
A1
No biomarker
Non Small Cell Lung Cancer
No biomarker
Non Small Cell Lung Cancer
ramucirumab
Sensitive: A1 - Approval
ramucirumab
Sensitive
:
A1
ramucirumab
Sensitive: A1 - Approval
ramucirumab
Sensitive
:
A1
No biomarker
Non Small Cell Lung Cancer
No biomarker
Non Small Cell Lung Cancer
durvalumab
Sensitive: A1 - Approval
durvalumab
Sensitive
:
A1
durvalumab
Sensitive: A1 - Approval
durvalumab
Sensitive
:
A1
No biomarker
Renal Cell Carcinoma
No biomarker
Renal Cell Carcinoma
nivolumab + cabozantinib tablet
Sensitive: A1 - Approval
nivolumab + cabozantinib tablet
Sensitive
:
A1
nivolumab + cabozantinib tablet
Sensitive: A1 - Approval
nivolumab + cabozantinib tablet
Sensitive
:
A1
No biomarker
Malignant Pleural Mesothelioma
No biomarker
Malignant Pleural Mesothelioma
nivolumab + ipilimumab
Sensitive: A1 - Approval
nivolumab + ipilimumab
Sensitive
:
A1
nivolumab + ipilimumab
Sensitive: A1 - Approval
nivolumab + ipilimumab
Sensitive
:
A1
No biomarker
Follicular Lymphoma
No biomarker
Follicular Lymphoma
axicabtagene ciloleucel
Sensitive: A1 - Approval
axicabtagene ciloleucel
Sensitive
:
A1
axicabtagene ciloleucel
Sensitive: A1 - Approval
axicabtagene ciloleucel
Sensitive
:
A1
No biomarker
Diffuse Large B Cell Lymphoma
No biomarker
Diffuse Large B Cell Lymphoma
axicabtagene ciloleucel
Sensitive: A1 - Approval
axicabtagene ciloleucel
Sensitive
:
A1
axicabtagene ciloleucel
Sensitive: A1 - Approval
axicabtagene ciloleucel
Sensitive
:
A1
No biomarker
Mediastinal B Cell Lymphoma
No biomarker
Mediastinal B Cell Lymphoma
axicabtagene ciloleucel
Sensitive: A1 - Approval
axicabtagene ciloleucel
Sensitive
:
A1
axicabtagene ciloleucel
Sensitive: A1 - Approval
axicabtagene ciloleucel
Sensitive
:
A1
No biomarker
Gastroesophageal Junction Adenocarcinoma
No biomarker
Gastroesophageal Junction Adenocarcinoma
nivolumab
Sensitive: A1 - Approval
nivolumab
Sensitive
:
A1
nivolumab
Sensitive: A1 - Approval
nivolumab
Sensitive
:
A1
No biomarker
Esophageal Cancer
No biomarker
Esophageal Cancer
nivolumab
Sensitive: A1 - Approval
nivolumab
Sensitive
:
A1
nivolumab
Sensitive: A1 - Approval
nivolumab
Sensitive
:
A1
No biomarker
Esophageal Squamous Cell Carcinoma
No biomarker
Esophageal Squamous Cell Carcinoma
nivolumab
Sensitive: A1 - Approval
nivolumab
Sensitive
:
A1
nivolumab
Sensitive: A1 - Approval
nivolumab
Sensitive
:
A1
No biomarker
Fallopian Tube Cancer
No biomarker
Fallopian Tube Cancer
niraparib
Sensitive: A1 - Approval
niraparib
Sensitive
:
A1
niraparib
Sensitive: A1 - Approval
niraparib
Sensitive
:
A1
No biomarker
Ovarian Cancer
No biomarker
Ovarian Cancer
niraparib
Sensitive: A1 - Approval
niraparib
Sensitive
:
A1
niraparib
Sensitive: A1 - Approval
niraparib
Sensitive
:
A1
No biomarker
Peritoneal Cancer
No biomarker
Peritoneal Cancer
niraparib
Sensitive: A1 - Approval
niraparib
Sensitive
:
A1
niraparib
Sensitive: A1 - Approval
niraparib
Sensitive
:
A1
No biomarker
Mantle Cell Lymphoma
No biomarker
Mantle Cell Lymphoma
brexucabtagene autoleucel
Sensitive: A1 - Approval
brexucabtagene autoleucel
Sensitive
:
A1
brexucabtagene autoleucel
Sensitive: A1 - Approval
brexucabtagene autoleucel
Sensitive
:
A1
No biomarker
Marginal Zone Lymphoma
No biomarker
Marginal Zone Lymphoma
rituximab + lenalidomide
Sensitive: A1 - Approval
rituximab + lenalidomide
Sensitive
:
A1
rituximab + lenalidomide
Sensitive: A1 - Approval
rituximab + lenalidomide
Sensitive
:
A1
No biomarker
Esophageal Adenocarcinoma
No biomarker
Esophageal Adenocarcinoma
nivolumab
Sensitive: A1 - Approval
nivolumab
Sensitive
:
A1
nivolumab
Sensitive: A1 - Approval
nivolumab
Sensitive
:
A1
No biomarker
Non-Hodgkin’s Lymphoma
No biomarker
Non-Hodgkin’s Lymphoma
brentuximab vedotin
Sensitive: A1 - Approval
brentuximab vedotin
Sensitive
:
A1
brentuximab vedotin
Sensitive: A1 - Approval
brentuximab vedotin
Sensitive
:
A1
No biomarker
Gastric Cancer
No biomarker
Gastric Cancer
nivolumab
Sensitive: A1 - Approval
nivolumab
Sensitive
:
A1
nivolumab
Sensitive: A1 - Approval
nivolumab
Sensitive
:
A1
No biomarker
Non Small Cell Lung Cancer
No biomarker
Non Small Cell Lung Cancer
bevacizumab
Sensitive: A1 - Approval
bevacizumab
Sensitive
:
A1
bevacizumab
Sensitive: A1 - Approval
bevacizumab
Sensitive
:
A1
No biomarker
Non Small Cell Lung Cancer
No biomarker
Non Small Cell Lung Cancer
nivolumab + ipilimumab
Sensitive: A1 - Approval
nivolumab + ipilimumab
Sensitive
:
A1
nivolumab + ipilimumab
Sensitive: A1 - Approval
nivolumab + ipilimumab
Sensitive
:
A1
No biomarker
Small Cell Lung Cancer
No biomarker
Small Cell Lung Cancer
durvalumab
Sensitive: A1 - Approval
durvalumab
Sensitive
:
A1
durvalumab
Sensitive: A1 - Approval
durvalumab
Sensitive
:
A1
No biomarker
Squamous Cell Carcinoma of Head and Neck
No biomarker
Squamous Cell Carcinoma of Head and Neck
cisplatin + docetaxel + 5-fluorouracil
Sensitive: A1 - Approval
cisplatin + docetaxel + 5-fluorouracil
Sensitive
:
A1
cisplatin + docetaxel + 5-fluorouracil
Sensitive: A1 - Approval
cisplatin + docetaxel + 5-fluorouracil
Sensitive
:
A1
No biomarker
Gastric Adenocarcinoma
No biomarker
Gastric Adenocarcinoma
cisplatin + docetaxel + 5-fluorouracil
Sensitive: A1 - Approval
cisplatin + docetaxel + 5-fluorouracil
Sensitive
:
A1
cisplatin + docetaxel + 5-fluorouracil
Sensitive: A1 - Approval
cisplatin + docetaxel + 5-fluorouracil
Sensitive
:
A1
No biomarker
Gastroesophageal Junction Adenocarcinoma
No biomarker
Gastroesophageal Junction Adenocarcinoma
cisplatin + docetaxel + 5-fluorouracil
Sensitive: A1 - Approval
cisplatin + docetaxel + 5-fluorouracil
Sensitive
:
A1
cisplatin + docetaxel + 5-fluorouracil
Sensitive: A1 - Approval
cisplatin + docetaxel + 5-fluorouracil
Sensitive
:
A1
No biomarker
Non Small Cell Lung Cancer
No biomarker
Non Small Cell Lung Cancer
cisplatin + pemetrexed
Sensitive: A1 - Approval
cisplatin + pemetrexed
Sensitive
:
A1
cisplatin + pemetrexed
Sensitive: A1 - Approval
cisplatin + pemetrexed
Sensitive
:
A1
No biomarker
Breast Cancer
No biomarker
Breast Cancer
docetaxel + doxorubicin hydrochloride + cyclophosphamide
Sensitive: A1 - Approval
docetaxel + doxorubicin hydrochloride + cyclophosphamide
Sensitive
:
A1
docetaxel + doxorubicin hydrochloride + cyclophosphamide
Sensitive: A1 - Approval
docetaxel + doxorubicin hydrochloride + cyclophosphamide
Sensitive
:
A1
No biomarker
Basal Cell Carcinoma
No biomarker
Basal Cell Carcinoma
fluorouracil topical
Sensitive: A1 - Approval
fluorouracil topical
Sensitive
:
A1
fluorouracil topical
Sensitive: A1 - Approval
fluorouracil topical
Sensitive
:
A1
No biomarker
Lung Non-Squamous Non-Small Cell Cancer
No biomarker
Lung Non-Squamous Non-Small Cell Cancer
pemetrexed
Sensitive: A1 - Approval
pemetrexed
Sensitive
:
A1
pemetrexed
Sensitive: A1 - Approval
pemetrexed
Sensitive
:
A1
No biomarker
Lung Non-Squamous Non-Small Cell Cancer
No biomarker
Lung Non-Squamous Non-Small Cell Cancer
cisplatin
Sensitive: A1 - Approval
cisplatin
Sensitive
:
A1
cisplatin
Sensitive: A1 - Approval
cisplatin
Sensitive
:
A1
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login